Market overview
The global nuclear medicine market is worth USD 4.0 bn in 2026 and is forecast to reach USD 7.4 bn by 2036, growing at a 6.2% CAGR. United States is the largest country market and PET/CT and PET/MR is the largest by modality segment.
| Scope | Imaging systems and associated software for nuclear medicine: gamma cameras, SPECT, SPECT/CT, PET/CT and PET/MR scanners sold to hospitals and imaging centres. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 3.8 bn |
| Value 2026 | USD 4.0 bn |
| Value 2036 | USD 7.4 bn |
| CAGR 2026-2036 | 6.2% |
| Volume 2026 | 3,463 units |
| Volume 2036 | 5,722 units |
| Average price 2026 | USD 1,163,000 per unit |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Nuclear Medicine market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 4.0 bn |
| 2027 | USD 4.3 bn |
| 2028 | USD 4.5 bn |
| 2029 | USD 4.8 bn |
| 2030 | USD 5.1 bn |
| 2031 | USD 5.4 bn |
| 2032 | USD 5.8 bn |
| 2033 | USD 6.1 bn |
| 2034 | USD 6.5 bn |
| 2035 | USD 6.9 bn |
| 2036 | USD 7.4 bn |
Nuclear Medicine market segmentation
By modality
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| PET/CT and PET/MR | 50.0% | 58.3% | USD 2.0 bn | 7.8% |
| SPECT and SPECT/CT | 42.0% | 36.9% | USD 1.7 bn | 4.8% |
| Planar gamma cameras | 8.0% | 4.8% | USD 322 mn | 0.8% |
By application
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Oncology | 48.0% | 52.7% | USD 1.9 bn | 7.2% |
| Cardiology | 28.0% | 24.3% | USD 1.1 bn | 4.7% |
| Neurology | 14.0% | 14.7% | USD 564 mn | 6.7% |
| Other | 10.0% | 8.3% | USD 403 mn | 4.2% |
By end user
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Hospitals | 68.0% | 65.0% | USD 2.7 bn | 5.7% |
| Imaging centres | 24.0% | 27.7% | USD 967 mn | 7.7% |
| Research institutes | 8.0% | 7.3% | USD 322 mn | 5.2% |
By isotope
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Technetium-99m | 48.0% | 40.0% | USD 1.9 bn | 4.3% |
| Fluorine-18 | 24.0% | 26.0% | USD 967 mn | 7.0% |
| Lutetium and gallium isotopes | 12.0% | 18.0% | USD 483 mn | 10.6% |
| Iodine and others | 16.0% | 16.0% | USD 644 mn | 6.2% |
By use
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Diagnostic SPECT | 40.0% | 32.0% | USD 1.6 bn | 3.9% |
| Diagnostic PET | 30.0% | 32.0% | USD 1.2 bn | 6.9% |
| Therapeutic radiopharmaceuticals | 30.0% | 36.0% | USD 1.2 bn | 8.2% |
Top 25 countries for nuclear medicine by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 84.5% of 2026 revenue and the 25 countries below together hold 96.0%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 1.4 bn | 34.0% | USD 2.3 bn | 5.3% |
| 2 | China | USD 644 mn | 16.0% | USD 1.6 bn | 9.3% |
| 3 | Japan | USD 322 mn | 8.0% | USD 470 mn | 3.9% |
| 4 | Germany | USD 282 mn | 7.0% | USD 448 mn | 4.8% |
| 5 | France | USD 161 mn | 4.0% | USD 257 mn | 4.8% |
| 6 | Italy | USD 141 mn | 3.5% | USD 228 mn | 4.9% |
| 7 | United Kingdom | USD 141 mn | 3.5% | USD 235 mn | 5.2% |
| 8 | South Korea | USD 121 mn | 3.0% | USD 221 mn | 6.2% |
| 9 | India | USD 121 mn | 3.0% | USD 323 mn | 10.3% |
| 10 | Brazil | USD 101 mn | 2.5% | USD 176 mn | 5.8% |
| 11 | Spain | USD 90 mn | 2.2% | USD 161 mn | 6.0% |
| 12 | Canada | USD 77 mn | 1.9% | USD 137 mn | 6.0% |
| 13 | Netherlands | USD 58 mn | 1.4% | USD 104 mn | 6.0% |
| 14 | Australia | USD 46 mn | 1.1% | USD 82 mn | 6.0% |
| 15 | Belgium | USD 37 mn | 0.9% | USD 68 mn | 6.1% |
| 16 | Turkey | USD 33 mn | 0.8% | USD 60 mn | 5.9% |
| 17 | Mexico | USD 26 mn | 0.7% | USD 47 mn | 6.0% |
| 18 | Poland | USD 21 mn | 0.5% | USD 37 mn | 6.0% |
| 19 | Switzerland | USD 17 mn | 0.4% | USD 30 mn | 5.9% |
| 20 | Sweden | USD 15 mn | 0.4% | USD 27 mn | 6.2% |
| 21 | Taiwan | USD 12 mn | 0.3% | USD 21 mn | 5.8% |
| 22 | Russia | USD 9.3 mn | 0.2% | USD 17 mn | 6.2% |
| 23 | Argentina | USD 8.5 mn | 0.2% | USD 15 mn | 5.7% |
| 24 | Israel | USD 7.2 mn | 0.2% | USD 12 mn | 5.6% |
| 25 | Austria | USD 5.2 mn | 0.1% | USD 9.6 mn | 6.2% |
| Rest of world | USD 162 mn | 4.0% | USD 290 mn | 6.0% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- GE HealthCare
- Siemens Healthineers
- Philips
- Canon Medical Systems
- United Imaging
Group 2: Regional and specialist players
- Mediso
- Spectrum Dynamics
- Neusoft Medical
- Capintec
- Shimadzu
Group 3: Emerging and niche players
- Comecer
- Raycan Technology
- Minfound Medical Systems
- Anzai Medical
- DDD-Diagnostic
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the nuclear medicine market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 6.2% is calculated from the resulting values.
The market is divided by modality, by application, by end user, by isotope, by use. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the nuclear medicine market?
The global nuclear medicine market is estimated at USD 3.8 bn in 2025 and USD 4.0 bn in 2026.
How fast will the nuclear medicine market grow?
It is forecast to reach USD 7.4 bn by 2036, a compound annual growth rate of 6.2% from 2026, an increase of USD 3.3 bn.
Which country is the largest market for nuclear medicine?
United States is the largest market by revenue at USD 1.4 bn in 2026, 34.0% of the global total. The three largest countries together hold 58.0%.
Which country is growing fastest?
Among the ten largest markets, India is growing fastest at 10.3% a year from 2026 to 2036.
Which nuclear medicine segment is largest?
In the by modality split, PET/CT and PET/MR is the largest segment with 50.0% of 2026 revenue.
Who are the leading nuclear medicine companies?
Global leaders include GE HealthCare, Siemens Healthineers, Philips, Canon Medical Systems.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Behavioral Health Continuum SolutionsUSD 4.0 bn · 10.5% CAGR
- Lower Limb Arterial Disease ManagementUSD 4.1 bn · 7.2% CAGR
- Biospecimen LogisticsUSD 3.9 bn · 9.0% CAGR
- Pharmaceutical SerializationUSD 3.7 bn · 9.0% CAGR
- AutoinjectorUSD 3.7 bn · 10.0% CAGR
- Safety SyringeUSD 4.5 bn · 8.0% CAGR
- ImmunohistochemistryUSD 3.5 bn · 8.0% CAGR
- Healthcare Provider Workflow OptimizationUSD 3.4 bn · 10.5% CAGR